HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Current Oncology · 02.06.2023 · 30 (6) · 5425-5447
DOI: 10.3390/curroncol30060411 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 02.06.2023. Verfasst von Katarzyna J Jerzak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre, Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Canada Inc..
Abstract (Originalsprache)
The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/HER2– advanced breast cancer in Canada based on relevant literature, clinical guidelines, and our own clinical experience. Due to statistically significant improvements in overall survival and progression-free survival, ribociclib + aromatase inhibitor is our preferred first-line treatment for de novo advanced disease or relapse ≥12 months after completion of adjuvant endocrine therapy and ribociclib or abemaciclib + fulvestrant is our preferred first-line treatment for patients experiencing early relapse. Abemaciclib or palbociclib may be used when alternatives to ribociclib are needed, and endocrine therapy can be used alone in the case of contraindication to CDK4/6 inhibitors or limited life expectancy. Considerations for special populations—including frail and fit elderly patients, as well as those with visceral disease, brain metastases, and oligometastatic disease—are also explored. For monitoring, we recommend an approach across CDK4/6 inhibitors. For mutational testing, we recommend routinely performing ER/PR/HER2 testing to confirm the subtype of advanced disease at the time of progression and to consider ESR1 and PIK3CA testing for select patients. Where possible, engage a multidisciplinary care team to apply evidence in a patient-centric manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Odette Cancer Centre, Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada.
- Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
- Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
- Dr. H. Bliss Murphy Cancer Center, St. John's, NL A1B 3V6, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
- Tom Baker Cancer Centre, Calgary AB T2N 4N2, Canada.
ORCID-Profile: Sandeep Sehdev
Förderung
- Novartis Pharmaceuticals Canada Inc.
Zitieren
APA
Jerzak, K. J., Bouganim, N., Brezden-Masley, C., Edwards, S., Gelmon, K., Henning, J. W., Hilton, J. F., & Sehdev, S. (2023). HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review. Current Oncology, 30(6), 5425-5447. https://doi.org/10.3390/curroncol30060411
Vancouver
Jerzak KJ, Bouganim N, Brezden-Masley C, Edwards S, Gelmon K, Henning JW, et al. HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review. Current Oncology. 2023;30(6):5425-5447. doi:10.3390/curroncol30060411
BibTeX
@article{Jerzak2023,
author = {Jerzak, Katarzyna J and Bouganim, Nathaniel and Brezden-Masley, Christine and Edwards, Scott and Gelmon, Karen and Henning, Jan-Willem and Hilton, John F and Sehdev, Sandeep},
title = {HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {6},
pages = {5425--5447},
doi = {10.3390/curroncol30060411}
}
EUVIMED